Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Many long noncoding RNAs have been reported to play pivotal roles in cancer biology. Among them, the long noncoding RNA
ZNFX1
-AS1 has been confirmed to function in breast cancer progression, but the role of
ZNFX1
-AS1 in
hepatocellular carcinoma
(
HCC
) growth and the related molecular mechanisms still remains unknown. In the present study, we first identified the expression of
ZNFX1
-AS1 in
HCC
patients' specimens and
HCC
cell lines through quantitative reverse transcription polymerase chain reaction. Next, the effects of
ZNFX1
-AS1 on
HCC
cell growth and apoptosis were analyzed. MTT assay was used to measure the cell numbers, and fluorescence-activated cell sorting analysis was performed to evaluate cell apoptosis. Finally, the relationship between
ZNFX1
-AS1 and miR-9 in
HCC
was studied. Our results suggest that
ZNFX1
-AS1 was markedly downregulated in
HCC
samples and cell lines. Overexpression of
ZNFX1
-AS1 inhibited the cell proliferation and colony formation in
HCC
cell lines and also induced
HCC
cell apoptosis. Additionally, miR-9 was lowly expressed in
HCC
tissues and positively correlated with
ZNFX1
-AS1 expression. Meanwhile, significant upregulation of miR-9 and downregulation of the methylation of miR-9 promoter CpG island were observed when
ZNFX1
-AS1 was overexpressed. In summary, our results indicate that
ZNFX1
-AS1 plays a vital role in
HCC
progression via regulating the methylation of miR-9 and may be a potential tumor suppressor.
...
PMID:Long noncoding RNA ZNFX1-AS1 suppresses growth of hepatocellular carcinoma cells by regulating the methylation of miR-9. 2757 42
Long non-coding RNAs (lncRNA) are classified as a kind of RNA, which are longer than 200 nucleotides in length and cannot be translated into proteins. Multiple studies have demonstrated that lncRNAs are involved in various cellular processes, including proliferation, differentiation, cell death, and metastasis. In addition, aberrant expression of lncRNAs has been discovered in human tumors, where they function as either oncogenes or tumor suppressor genes. Among numerous lncRNAs, we focus on
ZNFX1
antisense RNA 1 (
ZFAS1
), a well-known lncRNA that is aberrant overexpression in various tumors, including melanoma, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, colon cancer, and
Hepatocellular carcinoma
, in which it functions as oncogene. In contrast,
ZFAS1
is downregulated in breast cancer, which may function as tumor suppressor gene. In this review, we provide an overview of current evidence concerning the role and potential clinical utilities of
ZFAS1
in human cancers.
...
PMID:
ZFAS1
: a novel tumor-related long non-coding RNA. 3018 41
Numerous studies have reported that long noncoding RNA (lncRNA) dysregulation is involved in the progression of many malignant tumors, including glioma. The lncRNA
ZNFX1
antisense RNA 1 (ZFAS1) plays an oncogenic role in various malignant tumors, such as gastric cancer and
hepatocellular carcinoma
. However, the underlying molecular mechanism of ZFAS1 in glioma has not been fully clarified. In this study, we found that the expression of ZFAS1 was upregulated in both glioma tissues and cell lines. Functional experiments revealed that ZFAS1 promoted glioma proliferation, migration and invasion, and increased resistance to temozolomide in vitro. By using online databases, RNA pull-down assays and luciferase reporter assays, ZFAS1 was demonstrated to act as a sponge of miR-150-5p. Furthermore, proteolipid protein 2 (PLP2) was shown to be the functional target of miR-150-5p. Rescue experiments revealed that ZFAS1 regulated the expression of PLP2 by sponging miR-150-5p. Finally, a xenograft tumor assay demonstrated that ZFAS1 promoted glioma growth in vivo. Our results showed that ZFAS1 promoted glioma malignant progression by regulating the miR-150-5p/PLP2 axis, which may provide a potential therapeutic target for the treatment of glioma.
...
PMID:The long noncoding RNA ZFAS1 promotes the progression of glioma by regulating the miR-150-5p/PLP2 axis. 3153 80